A multicenter, open-label, uncontrolled, phase 1/2 study and extension study of ONO-5371 for symptoms of pheochromocytoma and paraganglioma caused by excess secretion of catecholamines
Latest Information Update: 29 Jun 2022
At a glance
- Drugs Metirosine (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 13 May 2022 Planned End Date changed from 1 Dec 2017 to 31 Jul 2019.
- 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
- 15 Jun 2016 New trial record